Barth Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Barth Syndrome Market Outlook

Thelansis’s “Barth Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Barth syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Barth Syndrome Overview

Barth syndrome (BTHS) is a rare X-linked genetic disorder that has distinct characteristics, including cardiomyopathy (CM), skeletal myopathy, growth delay, neutropenia, and elevated urinary levels of 3-methylglutaconic acid (3-MGCA). This condition arises from mutations in the TAZ gene (at Xq28), which encodes Taz1p acyltransferase, an enzyme crucial for cardiolipin metabolism—a major phospholipid in the inner mitochondrial membranes. Dysfunctional Taz1p leads to abnormal cardiolipin remodeling, compromising the integrity of mitochondrial structure and respiratory chain function. Clinical manifestations encompass a broad spectrum, with varying combinations of the following features: dilated cardiomyopathy (DCM), left ventricular non-compaction (LVNC), endocardial fibroelastosis (EFE), hypertrophic cardiomyopathy (HCM), ventricular arrhythmia, sudden cardiac death, neutropenia (ranging from absent to severe), delayed motor milestones, proximal myopathy, lethargy, fatigue, prolonged QTc interval, failure to thrive, compensatory monocytosis, recurrent bacterial infections, hypoglycemia, feeding difficulties, growth and pubertal delays, lactic acidosis, intermittent or perfectly cyclical symptoms like diarrhea, characteristic facial features, and a family history of X-linked inheritance. The average age at which BTHS is diagnosed falls between 4 and 5 years, even though symptoms typically occur between 0.7 and 1.5 years. Cardiomyopathy accounts for 70% of the primary reasons for pursuing DNA diagnostic testing to confirm BTHS. Other reported motivations for testing include neutropenia, growth delay/failure to thrive, and a family history of the condition.

• In the United States, around 10 new cases are diagnosed annually, and 71 distinct family lines have been identified. The Barth Syndrome Foundation (BSF) estimates that the prevalence of BTHS is approximately 1 in 300,000 to 400,000 live births in the USA.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: